Molecular targeted therapy has rapidly been developing in human intractable demyelinating diseases. However, it is still extremely difficult to cure demyelinating diseases and repair damaged tissues, especially progressive form of multiple sclerosis. To develop a novel therapy for intractable demyelinating diseases, it is critical to uncover novel target molecules involved in disease cascades. Large scale genetic studies and bioinformatics as well as genetically engineered animals are powerful tools for discovering novel risk molecules and examining functions of these molecules. Combined neuropathological and neuroimaging approaches are also useful to clarify disease cascades. In this symposium, four distinguished speakers give lectures on genetic, immunopathological, molecular imaging, and genetically engineered mouse approaches to identify novel molecules involved in pathomechanisms of human demyelinating diseases.

Molecular targeted therapy has rapidly been developing in human intractable demyelinating diseases. However, it is still extremely difficult to cure demyelinating diseases and repair damaged tissues, especially progressive form of multiple sclerosis. To develop a novel therapy for intractable demyelinating diseases, it is critical to uncover novel target molecules involved in disease cascades. Large scale genetic studies and bioinformatics as well as genetically engineered animals are powerful tools for discovering novel risk molecules and examining functions of these molecules. Combined neuropathological and neuroimaging approaches are also useful to clarify disease cascades. In this symposium, four distinguished speakers give lectures on genetic, immunopathological, molecular imaging, and genetically engineered mouse approaches to identify novel molecules involved in pathomechanisms of human demyelinating diseases.

Molecular targeted therapy has rapidly been developing in human intractable demyelinating diseases. However, it is still extremely difficult to cure demyelinating diseases and repair damaged tissues, especially progressive form of multiple sclerosis. To develop a novel therapy for intractable demyelinating diseases, it is critical to uncover novel target molecules involved in disease cascades. Large scale genetic studies and bioinformatics as well as genetically engineered animals are powerful tools for discovering novel risk molecules and examining functions of these molecules. Combined neuropathological and neuroimaging approaches are also useful to clarify disease cascades. In this symposium, four distinguished speakers give lectures on genetic, immunopathological, molecular imaging, and genetically engineered mouse approaches to identify novel molecules involved in pathomechanisms of human demyelinating diseases.

Molecular targeted therapy has rapidly been developing in human intractable demyelinating diseases. However, it is still extremely difficult to cure demyelinating diseases and repair damaged tissues, especially progressive form of multiple sclerosis. To develop a novel therapy for intractable demyelinating diseases, it is critical to uncover novel target molecules involved in disease cascades. Large scale genetic studies and bioinformatics as well as genetically engineered animals are powerful tools for discovering novel risk molecules and examining functions of these molecules. Combined neuropathological and neuroimaging approaches are also useful to clarify disease cascades. In this symposium, four distinguished speakers give lectures on genetic, immunopathological, molecular imaging, and genetically engineered mouse approaches to identify novel molecules involved in pathomechanisms of human demyelinating diseases.